Raltegravir: The evidence of its therapeutic value in HIV-1 infection

Core Evidence

Volumn 4, Issue , 2009, Pages 131-147

  Ramkumar, Kavya ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clinical evidence; HIV 1; Integrase inhibitor; Isentress; MK 0518; Raltegravir

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; NEVIRAPINE; OMEPRAZOLE; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION SENSITIVITY; KIDNEY FAILURE; LIPODYSTROPHY; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MULTIDRUG RESISTANCE; MYOPATHY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIMIZED BACKGROUND THERAPY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY OF LIFE; RASH; REVIEW; RHABDOMYOLYSIS; SALVAGE THERAPY; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 77954257512     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. UNAIDS. Report on the global HIV/AIDS epidemic 2008: executive summary. 2008. Accessed February 2008. Available from: http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp.
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
3. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106. (Pubitemid 351679596)
4. Emmelkamp JM, Rockstroh JK. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin Drug Safety. 2008;7:559-569.
5. Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis. 2008;47:969-978.
6. Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther. 2008;6:427-433.
7. Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. AIDS Patient Care STDS. 2008;22:459-471.
8. Montessori V, Press N, Harris M, Akagi LMontaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:229-238. (Pubitemid 38134804)
9. Young B. Review: mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS. 2005;19:286-297. (Pubitemid 40770652)
10. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394. (Pubitemid 34851830)
11. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:2039-2062.
12. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
13. Gross R, Yip B, Lo Re V 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-1114. (Pubitemid 44547650)
14. Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor [abstract]. Toronto, Canada: XVI International AIDS Conference; 2006. THAA0302.
15. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51:5843-5855.
16. Cabrera C. Raltegravir, an HIV-1 integrase inhibitor for HIV infection. Curr Opin Investig Drugs. 2008;9:885-898.
17. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008e;83:293-299.
18. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657-1663. (Pubitemid 47296061)
19. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515. (Pubitemid 44885615)
20. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133. (Pubitemid 47482607)
21. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data [abstract]. Mexico City, Mexico: XVII International AIDS Conference; 2008. TUAB0102.
22. Lennox J, Dejesus E, Lazzarin A, et al. STARTMRK, A Phase III Study of the Safety & Efficacy of Raltegravir (RAL)-Based vs Efavirenz (EFV)-Based Combination Therapy in Treatment-Naïve HIV-Infected Patients [abstract]. Washington, DC: 48th Annual ICAAC/IDSA 46th Annual Meeting; 2008. H-896a.
23. Lennox J, Dejesus E, Lazzarin A, et al. Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenz-based Combination Therapy in Treatment-naïve HIV-infected Patients [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunisitic Infections; 2009. 573.
24. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269. (Pubitemid 46553846)
25. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
26. Steigbigel R, Cooper D, Eron J, et al. 96-week results from BENCHMRK 1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV [abstract]. 16th Conference on Retroviruses and Opportunistic Infections; 2009. 571B.
27. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315-2321. (Pubitemid 350287458)
28. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A. 2008;105:4832-4837. (Pubitemid 351753832)
29. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008b;22:1224-1226.
30. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in highly treatement experienced HIV-1-infected patients: a randomized open-label non-inferiority trial, EASIER - ANRS 138 [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunistic Infections; 2009. 572.
31. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination art resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada. 2009. Abstract 70aLB.
32. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914-920.
33. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS. 2008;22:1091-1092. (Pubitemid 351769751)
34. Goodman DD, Hluhanich R, Waters J, et al. Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance XVII International HIV Drug Resistance Workshop; Sitges, Spain. Antiviral Ther. 2008;13:A15.
35. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355-365.
36. Malet I, Delelis O, Valantin MA, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351-1358. (Pubitemid 351521998)
37. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-532. (Pubitemid 38971345)
38. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12:563-570. (Pubitemid 47041156)
39. Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol. 2008;82:9228-9235.
40. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS. 2008;22:1877-1880.
41. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008;47:9345-9354.
42. Zahm JA, Bera S, Pandey KK, et al. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother. 2008;52:3358-3368.
43. Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008c;47:137-140. (Pubitemid 351920602)
44. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52:3253-3258.
45. Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir [abstract]. Mexico City, Mexico: XVII International AIDS Conference; 2008. TUPE0087.
46. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008a;48:209-214.
47. Hazuda DJ, Iwamoto M, Wenning L. Emerging pharmacology: Inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol. 2008;49:377-394.
48. Anderson MS, Wenning LA, Moreau A, et al. Effect of raltegravir (RAL) on the pharmacokinetics (PK) of oral contraceptives [abstract]. Chicago, IL: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007. 4731.
49. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009b;48:489-492.
50. Teppler H, Azrolan N, Chen J, Nguyen NY. Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients [abstract]. San Francisco, CA: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. H-256a.
51. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ Jr. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22:1382-1384.
52. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008b;48:726-733. (Pubitemid 351713160)
53. Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008;28:90-101.
54. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008a;22:1890-1892.
55. Cooper D, Steigbigel R, Lennnox J, et al. Review of cancer incidence in raltegravir clinical trials [abstract]. Montreal, Canada: 16th Conference on Retroviruses and Opportunistic Infections; 2009. 859.
56. Common Drug Review. Raltegravir (IsentressTM - Merck Frosst Canada Ltd.), Indication - HIV infection: Overview of CDR and Pharmacoeconomic reports [July 2008]. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health; 2008.
57. Elbasha E, Szucs T, Chaudhary M, et al. Cost-effectiveness analysis of Raltegravir in treatment - experienced HIV-1 infected patients in Switzerland [abstract]. Mexico City, Mexico: Poster Discussion: AIDS 2008 - XVII International AIDS Conference;2008. TUPDD203.
58. Martin SC. Cost-minimization analysis of etravirine and raltegravir, two new HIV treatments for treatment-experienced patients. Value in Health. 2008;11:A438-A438.
59. Centers for Disease Control and Prevention. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: CDC, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008a. NGC:006760.
60. Centers for Disease Control and Prevention. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Bethesda, MD: CDC, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008b. NGC:006652.
61. New York State Department of Health. Drug-drug interactions between HAART, medications used in substance use treatment, and recreational drugs. New York, NY: New York State Department of Health. 2008. NGC:006471.
62. Anon. Raltegravir Prescribing Information. 2009. Accessed Feb 2009. Available from: http://www.merck.com/.
63. Iwamoto M, Hanley WD, Petry AS, et al. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother. 2009a;53:1747-1752.
64. Iwamoto M, Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008d;52:4338-4343.
65. Rhame F, Long M, Acosta E. RAL-KAL: pharmacokinetics of coadministered raltegravir and lopinavir-ritonavir in healthy adults [abstract]. New Orleans, LA: 9th International Workshop on Clinical Pharmacology of HIV Therapy; 2008. O19.
66. Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir (tpv + Rtv) on pharmacokinetics of MK-0518 [abstract]. San Francisco, CA: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. A374.
67. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008;52:4228-4232.